FDA neu­ro­science chief Bil­ly Dunn, who led Aduhelm ap­proval, will leave agency

The FDA’s top neu­ro­science ex­pert Bil­ly Dunn, who was em­broiled in con­tro­ver­sy over his close ties with in­dus­try ahead of two key Alzheimer’s drug ap­provals, has de­cid­ed to leave the agency ef­fec­tive im­me­di­ate­ly, ac­cord­ing to an in­ter­nal email ob­tained by End­points News.

“Bil­ly has de­cid­ed to re­tire from the FDA and ex­plore oth­er op­por­tu­ni­ties while con­tin­u­ing his fo­cus on im­prov­ing the lives of pa­tients with neu­ro­log­i­cal dis­eases,” Pe­ter Stein, head of the Of­fice of New Drugs, said in the email.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER